Equipoise is not an ideal steroid for the drug tested athlete however. This drug has the tendency to produce detectable metabolites in the urine months after use, a worry most commonly associated with Deca-Durabolin. This is of course due to the high oil solubility of long chain esterified injectable steroids, a property which enables the drug to remain deposited in fatty tissues for extended periods of time. While this will reliably slow the release of steroid into the blood stream, it also allows small residual amounts to remain present in the body far after the initial injection. The release of stubborn stores of hormone would no doubt also be enhanced around contest time, a period when the athlete drastically attempts to mobilize unwanted body fat. If enough were used in the off-season, the athlete may actually fail a drug screen for boldenone although many months may have past since the drug was last injected.
For instance, comparing an investigatorinitiated, observational trial to an industry-sponsored, premarket interventional trial illustrates how this framework might be used to qualify a PI. As depicted right, the competencies for the Study and Site Management Domain are identical in the two different styles of trial, but not so for the Scientific and Research Design Domain. This does not imply that a less competent investigator can perform an observational study, but that a lower level of competency is required for that study method. Furthermore, the level of competency might be quite different for other clinical research team roles, such as CRC, CRA, data manager, or regulatory affairs coordinator.